Biomarker ID | 1311 |
PMID | 24411283 |
Year | 2014 |
Biomarker | LMTK2 [SNP: rs6465657] |
Biomarker Basis | Mutation Based |
Biomolecule | Mutation |
Source | Blood |
Subjects | Humans |
Regulation | Decreased risk of PCa Specific Mortality |
Odds Ratio/Hazard Ratio/Relative Risk | HR: 0.90 (95% CI: 0.82–0.98) |
Effect on Pathways | Pathways include: IGF1R human kinase ARCHS4 coexpression, BRAF human kinase ARCHS4 coexpression, WNK2 human kinase ARCHS4 coexpression, PDPK1 human kinase ARCHS4 coexpression, WNK1 human kinase ARCHS4 coexpression |
Experiment | PCa Specific Mortality Vs No Mortality |
Type of Biomarker | Prognostic |
Cohort | 8 different cohorts from The Breast and Prostate Cancer Cohort Consortium were studied in this analysis. Overall 10487 cases were included out of which 1053 had PCa related deaths |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.02 |
Method Used | NA |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |